Table 6.
Summary of adverse events (all treated subjects with available toxicity data, n=38)
| Adverse event | Events, no. (%) |
||
|---|---|---|---|
| Grade 3 | Grade 4 | Grade 5 | |
| Blood/bone marrow | |||
| Neutropenia | 5 (13) | 11 (29) | 0 |
| Thrombocytopenia | 7 (18) | 6 (16) | 0 |
| Anemia | 6 (16) | 2 (5) | 0 |
| Cardiovascular | |||
| Hypertension | 1 (3) | 0 | 0 |
| Hepatic | |||
| Aspartate AT | 1 (3) | 1 (3) | 0 |
| Alanine AT | 1 (3) | 1 (3) | 0 |
| Bilirubin | 2 (5) | 0 | 0 |
| Infection (ANC greater than 500) | 1 (3) | 1 (3) | 0 |
| Febrile neutropenia | 3 (8) | 0 | 0 |
| Neurologic | |||
| Aphasia | 1 (3) | 0 | 0 |
| Hallucinations | 1 (3) | 0 | 0 |
| Depressed consciousness | 0 | 1 (3) | 0 |
| Depression | 1 (3) | 0 | 0 |
| Confusion | 1 (3) | 0 | 0 |
| Neuropathy, peripheral | 1 (3) | 0 | 0 |
| Seizure | 1 (3) | 0 | 0 |
| Constitutional/other | |||
| Diarrhea | 1 (3) | 0 | 0 |
| Fatigue | 6 (16) | 1 (3) | 0 |
| Muscle weakness | 4 (11) | 0 | 0 |
| Myalgia | 1 (3) | 0 | 0 |
AT indicates aminotransferase; ANC, absolute neutrophil count per microliter.